The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Study of JAK inhibition in stem-like prostate cancer (JASPER): A phase 1/2 multicenter study of ruxolitinib and enzalutamide in castration resistant prostate cancer undergoing lineage plasticity.
 
Thomas Westbrook
Honoraria - DAVA Oncology
Consulting or Advisory Role - Johnson & Johnson
Research Funding - Incyte
 
Frank Cackowski
Honoraria - HealthMotiv
 
Joshi Alumkal
Consulting or Advisory Role - FibroGen; ORIC Pharmaceuticals
Research Funding - NCCN/Pfizer; Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - ORIC Pharmaceuticals
 
Anbarasu Kumaraswamy
No Relationships to Disclose
 
Megan Caram
No Relationships to Disclose
 
Sarah Yentz
No Relationships to Disclose
 
Ulka Vaishampayan
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Janssen Oncology; Merck Serono; Mural; Pfizer; Pfizer/Astellas; Sumitomo Pharma Oncology
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Manjunath Pai
No Relationships to Disclose
 
Thomas Braun
Employment - Johnson & Johnson (I)
Consulting or Advisory Role - Roche Pharma AG
 
Zachery Reichert
Consulting or Advisory Role - AstraZeneca; Janssen Oncology
Research Funding - AstraZeneca (Inst)
Expert Testimony - Huff Bowell Bailey